Wellington Management Group LLP Has $96.94 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Wellington Management Group LLP reduced its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 44.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 704,175 shares of the biotechnology company's stock after selling 557,305 shares during the quarter. Wellington Management Group LLP owned about 1.16% of Ascendis Pharma A/S worth $96,944,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Zimmer Partners LP bought a new stake in shares of Ascendis Pharma A/S during the third quarter worth $11,646,000. XTX Topco Ltd bought a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at about $1,692,000. Main Management ETF Advisors LLC acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $927,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at $886,000. Finally, Nomura Asset Management Co. Ltd. raised its stake in Ascendis Pharma A/S by 42.5% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 18,000 shares of the biotechnology company's stock worth $2,688,000 after buying an additional 5,371 shares during the period.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. raised their price target on Ascendis Pharma A/S from $168.00 to $200.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 18th. The Goldman Sachs Group raised their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a report on Thursday, February 13th. Cantor Fitzgerald lifted their price target on Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research note on Tuesday, February 25th. UBS Group initiated coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They set a "buy" rating and a $196.00 price objective for the company. Finally, Morgan Stanley set a $180.00 price target on shares of Ascendis Pharma A/S in a research note on Tuesday, February 18th. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $204.64.

Remove Ads

Ascendis Pharma A/S Trading Up 4.2 %

Shares of ASND traded up $5.94 during mid-day trading on Tuesday, reaching $146.08. The company's stock had a trading volume of 157,235 shares, compared to its average volume of 472,243. Ascendis Pharma A/S has a 1-year low of $111.09 and a 1-year high of $169.37. The business has a 50-day simple moving average of $146.68 and a two-hundred day simple moving average of $137.84. The stock has a market cap of $8.87 billion, a P/E ratio of -20.62 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($1.32) by $0.64. Research analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.